Literature DB >> 22225470

Association of a TANK gene polymorphism with outcomes of hepatitis B virus infection in a Chinese Han population.

Qi-Long Song1, Xing-Xing He, Hong Yang, Jin Li, Man Chen, Meng-Yi Wang, Qing Liu, Jin-Ling Yu, Jin-Jian Yao, Li-Feng Liu, Shu-Zhen Sun, Ju-Sheng Lin.   

Abstract

The host genetic compound plays a vital role in determining clinical outcomes of hepatitis B virus (HBV) infection. The tumor necrosis factor receptor-associated factor family member-associated nuclear factor-κB (NF-κB) activator (TANK) takes part in the tumor necrosis factor-α (TNF-α)-mediated NF-κB signaling pathway and the interferon (IFN)-induction pathways that have relevance to HBV-related liver disease. In this report, we explored whether the intronic polymorphism rs3820998 of the TANK gene was associated with outcomes of HBV infection by binary logistic regression analysis. A total of 1305 unrelated Han Chinese patients recruited from Wuhan, including 180 acute-on-chronic hepatitis B liver failure (ACLF-HBV) patients, 331 HBV-related liver cirrhosis (LC) patients, 308 HBV-related hepatocellular carcinoma (HCC) patients, and 486 asymptomatic HBV carriers (AsC) were genotyped using the TaqMan probe method. Logistic analysis revealed that the single-nucleotide polymorphism (SNP) rs3820998 was significantly associated with susceptibility to ACLF-HBV (dominant model, OR 0.643, 95% CI 0.428,0.964, p=0.033; additive model, OR 0.640, 95% CI 0.414,0.990, p=0.045), and LC (recessive model, OR 0.398, 95% CI 0.164,0.966, p=0.042; additive model, OR 0.379, 95% CI 0.155,0.928, p=0.034). These results indicate that the G > T variant is a protective factor in the development of ACLF-HBV and LC, and that the SNP rs3820998 in the TANK gene may play a role in mediating susceptibility to ACLF-HBV and LC in a Chinese Han population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22225470     DOI: 10.1089/vim.2011.0053

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  7 in total

1.  Genetic variants that associate with cirrhosis have pleiotropic effects on human traits.

Authors:  Vincent L Chen; Yanhua Chen; Xiaomeng Du; Samuel K Handelman; Elizabeth K Speliotes
Journal:  Liver Int       Date:  2020-01-01       Impact factor: 5.828

2.  Initial combination anti-viral therapy with lamivudine and adefovir dipivoxil decreases short-term fatality rate of hepatitis-B-virus-related acute-on-chronic liver failure.

Authors:  Jiahong Yang; Gao Chen; Xuebing Chen; Hao Zhang; Di Jiang; Guang Yang
Journal:  Virol J       Date:  2015-06-24       Impact factor: 4.099

3.  Correlation between patatin-like phospholipase domain-containing protein 3 gene polymorphisms and liver cirrhosis in a chinese han population with chronic hepatitis B.

Authors:  Jin Tong; Jinjun Guo; Jun Hu; Sihui Hou; Yu Zhang; Qingling Li
Journal:  Hepat Mon       Date:  2014-08-17       Impact factor: 0.660

Review 4.  The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis.

Authors:  Jiao Yang; Hang Sun; Qi Liu
Journal:  Gastroenterol Res Pract       Date:  2016-04-11       Impact factor: 2.260

Review 5.  NFKB1 -94insertion/deletion ATTG polymorphism and cancer risk: Evidence from 50 case-control studies.

Authors:  Wen Fu; Zhen-Jian Zhuo; Yung-Chang Chen; Jinhong Zhu; Zhang Zhao; Wei Jia; Jin-Hua Hu; Kai Fu; Shi-Bo Zhu; Jing He; Guo-Chang Liu
Journal:  Oncotarget       Date:  2017-02-07

6.  Identification of a 14-Gene Prognostic Signature for Diffuse Large B Cell Lymphoma (DLBCL).

Authors:  Pengcheng Feng; Hongxia Li; Jinhong Pei; Yan Huang; Guixia Li
Journal:  Front Genet       Date:  2021-02-10       Impact factor: 4.599

7.  Genome-wide association study of antiphospholipid antibodies.

Authors:  M Ilyas Kamboh; Xingbin Wang; Amy H Kao; Michael M Barmada; Ann Clarke; Rosalind Ramsey-Goldman; Susan Manzi; F Yesim Demirci
Journal:  Autoimmune Dis       Date:  2013-02-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.